These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35197225)

  • 1. A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales.
    Rafia R; Martyn-St James M; Harnan S; Metry A; Hamilton J; Wailoo A
    Value Health; 2022 May; 25(5):761-769. PubMed ID: 35197225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study.
    Kelton K; Klein T; Murphy D; Belger M; Hille E; McCollam PL; Spiro T; Burge R
    Adv Ther; 2022 Jan; 39(1):562-582. PubMed ID: 34807369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remdesivir Treatment in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Comparative Analysis of In-hospital All-cause Mortality in a Large Multicenter Observational Cohort.
    Mozaffari E; Chandak A; Zhang Z; Liang S; Thrun M; Gottlieb RL; Kuritzkes DR; Sax PE; Wohl DA; Casciano R; Hodgkins P; Haubrich R
    Clin Infect Dis; 2022 Aug; 75(1):e450-e458. PubMed ID: 34596223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment.
    Polivka L; Gajdacsi J; Fazekas L; Sebok S; Barczi E; Hidvegi E; Sutto Z; Dinya E; Maurovich-Horvat P; Szabo AJ; Merkely B; Müller V
    J Glob Health; 2022 Aug; 12():05031. PubMed ID: 36040909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey.
    Oksuz E; Malhan S; Gonen MS; Kutlubay Z; Keskindemirci Y; Jarrett J; Sahin T; Ozcagli G; Bilgic A; Bibilik MO; Tabak F
    Adv Ther; 2021 Sep; 38(9):4935-4948. PubMed ID: 34379304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19.
    Whittington MD; Pearson SD; Rind DM; Campbell JD
    Value Health; 2022 May; 25(5):744-750. PubMed ID: 35190252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remdesivir and Mortality in Patients With Coronavirus Disease 2019.
    Diaz GA; Christensen AB; Pusch T; Goulet D; Chang SC; Grunkemeier GL; McKelvey PA; Robicsek A; French T; Parsons GT; Doherty G; Laurenson C; Roper R; Hadlock J; Cover CJ; Footer B; Robinson P; Micikas M; Marfori JE; Cronenweth C; Mukkamala Y; Mackiewicz J; Rai E; Matson MD; Davila J; Rueda J; Tipton R; Algren H; Ward BC; Malkoski S; Gluckman T; Tallman GB; Arguinchona H; Hammond TC; Standaert S; Christensen J; Echaiz JF; Choi R; McClung D; Pacifico A; Fee M; Sarafian F; Berrington WR; Goldman JD
    Clin Infect Dis; 2022 May; 74(10):1812-1820. PubMed ID: 34409431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial.
    Lau VI; Fowler R; Pinto R; Tremblay A; Borgia S; Carrier FM; Cheng MP; Conly J; Costiniuk CT; Daley P; Duan E; Durand M; Fontela PS; Farjou G; Fralick M; Geagea A; Grant J; Keynan Y; Khwaja K; Lee N; Lee TC; Lim R; O'Neil CR; Papenburg J; Semret M; Silverman M; Sligl W; Somayaji R; Tan DHS; Tsang JLY; Weatherald J; Yansouni CP; Zarychanski R; Murthy S;
    CMAJ Open; 2022; 10(3):E807-E817. PubMed ID: 36199248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Baricitinib Compared With Standard of Care: A Modeling Study in Hospitalized Patients With COVID-19 in the United States.
    Ohsfeldt R; Kelton K; Klein T; Belger M; Mc Collam PL; Spiro T; Burge R; Ahuja N
    Clin Ther; 2021 Nov; 43(11):1877-1893.e4. PubMed ID: 34732289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of anti-viral therapies in hospitalised COVID-19 patients in the United Arab Emirates: a cost-effectiveness and health-care resource use analysis.
    Subhi A; Shamy AME; Hussein SAM; Jarrett J; Kozma S; Harfouche C; Al Dallal S
    BMC Health Serv Res; 2023 Apr; 23(1):383. PubMed ID: 37081467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study.
    Carta A; Conversano C
    BMC Health Serv Res; 2021 Sep; 21(1):986. PubMed ID: 34537034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis.
    Congly SE; Varughese RA; Brown CE; Clement FM; Saxinger L
    Sci Rep; 2021 Sep; 11(1):17787. PubMed ID: 34493774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 and kidney transplantation: the impact of remdesivir on renal function and outcome - a retrospective cohort study.
    Elec F; Magnusson J; Elec A; Muntean A; Antal O; Moisoiu T; Cismaru C; Lupse M; Oltean M
    Int J Infect Dis; 2022 May; 118():247-253. PubMed ID: 35301103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios.
    Jiang Y; Cai D; Chen D; Jiang S; Si L; Wu J
    Br J Clin Pharmacol; 2021 Nov; 87(11):4386-4396. PubMed ID: 33855727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative outcomes of combined corticosteroid and remdesivir therapy with corticosteroid monotherapy in ventilated COVID-19 patients.
    Mandadi S; Pulluru H; Annie F
    PLoS One; 2022; 17(2):e0264301. PubMed ID: 35196344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compassionate use of remdesivir in children with COVID-19.
    Méndez-Echevarría A; Pérez-Martínez A; Gonzalez Del Valle L; Ara MF; Melendo S; Ruiz de Valbuena M; Vazquez-Martinez JL; Morales-Martínez A; Remesal A; Sándor-Bajusz KA; Cabañas F; Calvo C
    Eur J Pediatr; 2021 Apr; 180(4):1317-1322. PubMed ID: 33200304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness Analysis and Impact on Length of Hospital Stay of the Introduction of Remdesivir as a Treatment Option for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen in Greece Versus Standard of Care.
    Athanasakis K; Zisis K; Tsoulas C; Nomikos N
    Clin Ther; 2023 Dec; 45(12):1244-1250. PubMed ID: 37914586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary trabeculectomy versus primary glaucoma eye drops for newly diagnosed advanced glaucoma: TAGS RCT.
    King AJ; Fernie G; Hudson J; Kernohan A; Azuara-Blanco A; Burr J; Homer T; Shabaninejad H; Sparrow JM; Garway-Heath D; Barton K; Norrie J; McDonald A; Vale L; MacLennan G
    Health Technol Assess; 2021 Nov; 25(72):1-158. PubMed ID: 34854808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.